Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 4/21/2016 |
| Start Date: | August 2005 |
| End Date: | March 2013 |
Molecular Epidemiology of Barrett's Esophagus
RATIONALE: A study that evaluates DNA changes and other disease-related health information
in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding
may help doctors learn more about the risk factors for Barrett's esophagus.
PURPOSE: This clinical trial is looking at DNA changes and other disease-related health
information as risk factors for Barrett's esophagus in patients with Barrett's esophagus,
gastroesophageal reflux, or gastrointestinal bleeding.
in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding
may help doctors learn more about the risk factors for Barrett's esophagus.
PURPOSE: This clinical trial is looking at DNA changes and other disease-related health
information as risk factors for Barrett's esophagus in patients with Barrett's esophagus,
gastroesophageal reflux, or gastrointestinal bleeding.
OBJECTIVES:
- Assess the role of several genetically determined factors that, in combination with
CagA status, cigarette smoking, alcohol, and diet to varying degrees, result in an
increased risk for Barrett's esophagus.
OUTLINE: This is a controlled study.
Patients complete questionnaires about demographics, medical history, smoking and alcohol
history, current medications, frequency and chronicity of gastroesophageal reflux symptoms,
and diet history.
Blood and tissue are collected and analyzed by DNA-based assays and enzyme-linked
immunosorbent assay for CagA status and polymorphisms in detoxifying enzyme systems, other
xenobiotic metabolism pathways (e.g., CYP1A1, CYP2E1, CYP3A4, CYP3A5, NQO, NAT-2),
inflammatory gene pathways (e.g., IGF, IGFBF3), and in DNA repair genes or p53 pathways
(e.g., XRCC1, p53 gene).
PROJECTED ACCRUAL: A total of 350 patients will be accrued for this study.
- Assess the role of several genetically determined factors that, in combination with
CagA status, cigarette smoking, alcohol, and diet to varying degrees, result in an
increased risk for Barrett's esophagus.
OUTLINE: This is a controlled study.
Patients complete questionnaires about demographics, medical history, smoking and alcohol
history, current medications, frequency and chronicity of gastroesophageal reflux symptoms,
and diet history.
Blood and tissue are collected and analyzed by DNA-based assays and enzyme-linked
immunosorbent assay for CagA status and polymorphisms in detoxifying enzyme systems, other
xenobiotic metabolism pathways (e.g., CYP1A1, CYP2E1, CYP3A4, CYP3A5, NQO, NAT-2),
inflammatory gene pathways (e.g., IGF, IGFBF3), and in DNA repair genes or p53 pathways
(e.g., XRCC1, p53 gene).
PROJECTED ACCRUAL: A total of 350 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Undergoing elective esophagogastroduodenoscopy for any of the following reasons:
- Surveillance of Barrett's esophagus
- Evaluation of severe or refractory gastroesophageal reflux disease or chest pain
thought to be due to reflux
- Gastrointestinal bleeding
PATIENT CHARACTERISTICS:
- Not pregnant
PRIOR CONCURRENT THERAPY:
- Not specified
We found this trial at
2
sites
Click here to add this to my saved trials
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials